# Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma

> **NCT04162158** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** allogeneic NK cells therapy

## Key facts

- **NCT ID:** NCT04162158
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162158, "Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04162158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*